Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016| Dave Fornell

Update for LAA Occluder Technology News and Trends

Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the left atrial appendage (LAA). The standard of care is use of warfarin or newer anticoagulation therapy agents, but there has been growing interest in eliminating the need for these drugs and their associated increased bleeding risks by closing off the LAA to prevent clot formation. Device therapy now exists for both open surgical and transcatheter LAA occlusion. 

Below are links to recent DAIC articles that offer an update on this cardiovascular technology area:

 

Occluding the Left Atrial Appendage (LAA)

VIDEO - Post-FDA Approval Experience of LAA Occluders at ACC.16

FDA Approves Pivotal Trial for St, Jude's Amulet LAA Occluder

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Societies Issue Recommendations for Left Atrial Appendage Occlusion

Biosense Webster Acquires Coherex Medical LAA Occluder Technology

Medicare Will Cover Watchman Left Atrial Appendage Closure Device

AtriCure Receives FDA Clearance for New AtriClip Device

New Study Demonstrates Cost-Effectiveness of Watchman Device

Boston Scientific Receives CE Mark For Next-generation Watchman FLX LAA Closure Device

FDA Announces Safety Issues With Lariat Left Atrial Appendage (LAA) Closure Device

SentreHeart Receives CE Mark for Lariat Suture Delivery Device

AtriCure Receives CE Mark for AtriClip PRO2 Device

New Data Supports St. Jude Medical FFR and LAA Closure Technology

AtriCure Announces First Patient Enrolled in FROST Cryoanalgesia Study

SentreHEART Receives FDA Approval for AMAZE Trial of Lariat Suture Delivery Device

Valley Hospital Begins Enrollment for aMAZE Trial

AtriCure Enrolls First Patient in ATLAS Study

Role of Interventional Echocardiography in Transcatheter Structural Heart Procedures

 

Related Content

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Overlay Init